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ABSTRACT 
Gene therapy became in last decade a new emerging therapeutic era showing promising results against different 
diseases such as cancer, cardiovascular diseases, diabetes, and neurological disorders. Recently, the genome edit-
ing technique for eukaryotic cells called CRISPR-Cas (Clustered Regulatory Interspaced Short Palindromic Re-
peats) has enriched the field of gene surgery with enhanced applications. In the present review, we summarized 
the different applications of gene surgery for treating human diseases such as cancer, diabetes, nervous, and car-
diovascular diseases, besides the molecular mechanisms involved in these important effects. Several studies sup-
port the important therapeutic applications of gene surgery in a large number of health disorders and diseases in-
cluding β-thalassemia, cancer, immunodeficiencies, diabetes, and neurological disorders. In diabetes, gene sur-
gery was shown to be effective in type 1 diabetes by triggering different signaling pathways. Furthermore, gene 
surgery, especially that using CRISPR-Cas possessed important application on diagnosis, screening and treat-
ment of several cancers such as lung, liver, pancreatic and colorectal cancer. Nevertheless, gene surgery still pre-
sents some limitations such as the design difficulties and costs regarding ZFNs (Zinc Finger Nucleases) and 
TALENs (Transcription Activator-Like Effector Nucleases) use, off-target effects, low transfection efficiency, in 
vivo delivery-safety and ethical issues.  
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INTRODUCTION 
A gene is an expressed DNA sequence 
that can code for a protein or generate non-
coding RNA sequences (ncRNA). In general, 
eukaryotic genes consist of an alternation of 
multiple exons (coding sequence, transcript 
and translated) and introns, besides the regu-
lation and promoter sequences. Although in-
trons are considered noncoding or interven-
ing sequences, it has been demonstrated that 
they are able to regulate gene expression 
through the intron-mediated enhancement 
characterized by an mRNA accumulation 
(Shaul, 2017; Gallegos and Rose, 2015). 
Gene’s mutations are considered causes 
of several diseases such as cancer. Indeed, 
for example, DNA methylation has been 
demonstrated to be involved in at least 18 
cancer types (Chen et al., 2017). Genomic 
instability including chromosome and mi-
crosatellite instabilities and increased fre-
quencies of base-pair mutation is a hallmark 
of most cancer cells (Yao and Dai, 2014). 
Recently, in the most comprehensive study 
of gene mutations, 3400 driver mutations 
were found to be associated with 33 various 
cancer types (Bailey et al., 2018).  
Breast cancer has been linked to several 
mutations of the BRCA genes. BRCA 1 and 
BRCA 2, considered as tumor suppressor 
genes, are involved in the maintaining of ge-
netic stability by repairing DNA damages 
caused by environmental agents or even 
chromosomal events. BRCA 1 and 2 repair 
double-strand DNA breaks by homologous 
recombination repair. BRCA1 participates in 
DNA repair by neutralizing the Non-
homologous end joining (NHEJ) factor 
53BP1, whereas BRCA2 is involved in 
RAD51 filament assembly onto ssDNA 
(Chen et al., 2018). Consequently, BRCA 
mutations resulting in higher genetic insta-
bility and gross chromosomal rearrange-
ments, are linked to an enhanced risk of sev-
eral malignancies such as breast, ovarian, 
prostate and/pancreatic cancers (Solinas et 
al., 2019; Foulkes et al., 2016). BRCA muta-
tions cause homologous recombination re-
pair deficiency leading to carcinogenesis 
(Liposits et al., 2019). BRCA1/2 mutations 
are responsible for 15 % of triple-negative 
breast cancer cases and of 50 % of breast 
cancer cases in individuals with a strong 
family history (den Brok et al., 2017). Be-
sides their involvement in genetic predispo-
sition to cancers, BRCA 1/2 mutations are 
also considered promising targets of homol-
ogous recombination directed therapies such 
as PARP inhibitors (olaparib, rucaparib, and 
talazoparib for both breast and ovarian can-
cers) via the synthetic lethality (Sporikova et 
al., 2018; Riaz et al., 2017). 
Diabetes mellitus is a polygenic disease 
involving upregulation and/or downregula-
tion of a genes complex network 
(ADAMTS9, CDC123/CAMKID, JAZF1, 
NOTCH2, THADA, TSPAN8/LGRS, 
PPARG, ABCC8 and KCNJ11, PPARG, 
HMGA1, HNF4A, IRS1, HNF1A, AKT2, 
TCF7L2, IGF2BP2, MAPK8IP1, IRS2, 
NEUROD1, HNF1B, UBC, GCK, FGFR3, 
others) responsible for the occurrence, pro-
gression and complications of the disease 
(Gupta and Vadde, 2019; Peravali et al., 
2019).  
Type 1 diabetes mellitus is an auto-
immune disease characterized by failure in 
insulin production as a result of pancreatic 
insulin-secreting islet β cells destruction. In 
spite of its complex etiology, it has been 
demonstrated that various genes are involved 
in the apparition and development of this 
chronic disease. Indeed, downregulation of f 
insulin-like growth factor 1 (IGF1) and glu-
cose-6-phosphatase (G6Pase) genes, and also 
upregulation of the regenerating islet-derived 
protein 3 gamma gene (Reg3g) have been 
associated with type 1 diabetes mellitus 
(Chellappan et al., 2018). 
On the other hand, several genes and mu-
tations on they were found to play a crucial 
role in the development of type 2 diabetes. 
Indeed, it has been found that among 157 
genes studied in type 2 diabetic patients, 124 
had at least one mutation (Al-Rubeaan et al., 
2018). Among gene deregulations associated 
with type 2 diabetes are SIRT1, transcription 
factor 7-like2 (TCF7L2), Potassium channel 
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gene (KCNJ11), Glucocorticoid receptor 
(GRL), and Norepinephrine transporter 
(NET) (Karbasforooshan and Karimi, 2017). 
The high mobility group AT-hook1 
(HMGA1) gene codes for a 10 kDa multi-
functional non-histone chromatin protein 
implicated in various biological processes 
such as apoptosis, cell differentiation and 
DNA repair (Zhang et al., 2018; Fujikane et 
al., 2016). In addition to its role in oncology 
and inflammation, HMGA1 was found to be 
involved in the transcription of insulin recep-
tor INSR (as a sensor and regulator of insulin 
signaling), glucose homeostasis and there-
fore in type 2 diabetes development. It has 
been reported that HMGA1 deficiency leads 
to insulin resistance and type 2 diabetes both 
in humans and mice (Chiefari et al., 2018; 
Xue et al., 2018). 
Several nervous disorders have been 
found to be associated with gene mutations 
and/or deregulations (Wang et al., 2019; Eid 
et al., 2019). Parkinson’s disease character-
ized by dopamine deficiency has been linked 
to mutations in 10 genes: SNCA, LRRK2, 
PRKN, PINK1, DJ-1, ATP13A2, PLA2G6, 
FBXO7, GIGYF2, and UCHL1. Further-
more, genetic susceptibility to the disease 
has been shown to be related to various 
genes such as NR4A2, SNCAIP, APOE, 
MAPT, and GBA (Selvaraj and Pirama-
nayagam, 2019). On the other hand, genetic 
mutations have been linked to Alzheimer 
disease. It has been reported that at least, 117 
genes are related to Alzheimer disease 
(Grimm et al., 2019). Indeed, autosomal-
dominant early-onset Alzheimer disease has 
been found to be attributed to three genetic 
mutations: amyloid protein precursor (APP), 
presenilin-1 (PSEN1), and presenilin-2 
(PSEN2) (Lanoiselée et al., 2017). Besides, 
apolipoprotein E (ApoE) isomers have been 
demonstrated to be related to the develop-
ment of the disease in different populations 
(Ramadan et al., 2019). Sporadic Alz-
heimer’s disease susceptibility has been 
found to be attributed to several genes such 
as BIN1, CLU, PICALM, ABCA7, ABCG1, 
and SORL1 (Picard et al., 2018).  
Gene therapy refers to the insertion of 
normal genetic material into the cells of the 
patient to induce the expression of a genetic 
sequence responsible to achieve a therapeu-
tic effect. Gene augmentation therapy (gene 
replacement or addition), genes specific tar-
geted therapy, and genome editing or correc-
tion therapy are possible approaches as gene 
therapy (Lee et al., 2018; Lin et al., 2018).  
With more than 2597 clinical trials car-
ried out in 38 countries (Ginn et al., 2018), 
gene therapy continues to provide promising 
positive results regarding the treatment of 
various diseases such as retinal diseases, 
primary immunodeficiencies, neurological 
disorders, β-thalassemia, hemophilia, diabe-
tes, and cancers (Tan et al., 2019; Kumar et 
al., 2016). 
 
GENE SURGERY 
The genome-editing technique for eukar-
yotic cells called CRISPR-Cas has advanced 
the field of genetic engineering owing to the 
potential to generate cellular models more 
related to in vivo system than ever before 
(Dai et al., 2018; Erard et al., 2017; 
Wangensteen et al., 2018; Long et al., 2014; 
Wu et al., 2013; Freiermuth et al., 2018). 
Described in bacteria and archaea (Ishino et 
al., 1987; Mojica et al., 2000), this system 
possesses a particular configuration of a 
Clustered Regulatory Interspaced Short Pal-
indromic Repeats (CRISPR) and a endonu-
clease regulatory protein called as Cas 
(CRISPR-associated) (Jansen et al., 2002; 
Semenova et al., 2011; Hsu et al., 2014). 
CRISPR locus was first described as short 
repeats interspaced by unique extrachromo-
somal sequences from host organisms that 
confer immunity against plasmid or bacteri-
ophage infection (Bolotin et al., 2005). The 
spacers match with sequences from phages 
and plasmids (Wei et al. 2013) rising the hy-
pothesis that the CRISPR-Cas mechanism is 
an adaptive immune response of prokaryotes 
(Barrangou et al., 2007; Sampson and Weiss, 
2014; Sürün et al., 2018).  
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Briefly, the CRISPR-Cas defense is 
based on adaptation, biogenesis of crRNA 
(CRISPR-derived RNA) and action against 
the invader. In the first phase, a new spacer 
is acquired in CRISPR locus through cleav-
age and integration of a foreign DNA. In the 
second step, the CRISPR is transcribed in a 
long pre-crRNA which is processed in many 
small crRNAs, each one with a distinct spac-
er flanked by repeated fragments. Finally, 
Cas proteins interact with crRNAs, that drive 
the cleavages of invader DNA by the endo-
nuclease (Wiedenheft et al., 2012; Karvelis 
et al., 2013; Sampson and Weiss, 2014; 
Wiles et al., 2015; Sürün et al., 2018). 
Multiple and diverse CRISPR-Cas sys-
tems are defined by different Cas proteins 
and crRNA biogenesis (Makarova et al., 
2015; Carte et al., 2014). In Type I, Cas6 
cleaves the pre-crRNA and the mature guide 
combines with a CRISPR-associated com-
plex for antiviral defense (Cascade). The se-
quence-specific cleavage is mediated by the 
Cas3 protein which needs a short DNA motif 
called Protospacer Adjunct Motif (PAM) for 
target recognition. In Type III the pre-
crRNA is processed by Cas6, however, the 
ribonucleoprotein complex includes Cas10 
and the accessory genes Csm (III-A – DNA 
cleavage) and Crm (III-B – RNA cleavage) 
(Makarova et al., 2015; Karvelis et al., 2013; 
Jiang and Marraffini, 2015; Carte et al., 
2014). Type II is the simplest mechanism 
that consists of a crRNA maturation pathway 
including an additional Trans-activating 
CRISPR RNA molecule (tracrRNA) and the 
host RNase III. Besides, a single Cas9 pro-
vides target DNA cleavage (Karvelis et al., 
2013; Cong et al., 2013; Carte et al., 2014).  
In this system, CRISPR locus produces 
the tracrRNA with repeat sequences anneal-
ing to the repeat sequences of pre-crRNA. 
The Cas9 binds the tracrRNA and the dsR-
NA (tracrRNA plus pre-crRNA) is cleavage 
by RNase III, generating a Cas9 loaded with 
tracrRNA and crRNA guide (Jiang and 
Marraffini, 2015; Carte et al., 2014; Jinek et 
al., 2012). The endonuclease Cas9 needs the 
PAM motif in the 3’end of the target (Jinek 
et al., 2012; La Russa and Qi, 2015; Ehrke-
Schulz et al., 2017). The most efficient PAM 
sequence essential for Cas9 binding to the 
DNA is any nucleotide together with two 
guanines (NGG) (Jinek et al., 2012; La 
Russa and Qi, 2015; Anders et al., 2014; 
Larson et al., 2013). The tracrRNA/crRNA/ 
Cas9 ribonucleoprotein scans the target ge-
nome for PAM sequences and binds imme-
diately upstream of this motif (Anders et al., 
2014; Yuen et al., 2017). Cas9 has two en-
donuclease domains (RuvC and HNH) that 
cut both DNA strands and tracrRNA acts as 
a cofactor (Jiang and Marraffini, 2015; Jinek 
et al., 2012). The RuvC, HNH, and PAM-
interacting domains are in the nuclease 
(NUC) lobe of Cas9 that contains also the 
recognition lobe (REC) (Dai et al., 2018; 
Jinek et al., 2012). 
Based on this natural mechanism, 
CRISPR technique was developed involving 
a nuclease (usually Cas9 from Streptococcus 
pyogenes), a single-guide RNA (sgRNA) and 
the target in the genome (Gilbert et al., 2013; 
Hsu et al., 2014; Platt et al., 2014; Pelletier 
et al., 2015; Kocher et al., 2017; Sürün et al., 
2018). The sgRNA is a chimeric molecule 
made up of crRNA and tracrRNA, which is 
engineered and programmed to target with 
the interested sequence, responsible for the 
duplex with the target of DNA, by Watson 
and Crick base pairs (Hsu et al., 2014; Jinek 
et al., 2012; La Russa and Qi, 2015; Perez-
Pinera et al., 2013). The sgRNA contains a 
seed-sequence with about eight nucleotides 
in the 5’ end, and the 3’end forms a scaffold 
with approximately 80 nucleotides in which 
Cas9 can fold into an active form (Semenova 
et al., 2011; Zeng et al., 2018; Jinek et al., 
2012). Stable RNA: DNA hybrid (sgRNA 
plus target DNA) leads to R-loop formation 
and conformational change of the enzyme 
(Zeng et al., 2018; Yuen et al., 2017; Hsu et 
al., 2014). Finally, coordinated firing of both 
RuvC and HNH nuclease domains results in 
DNA cleavage (Jiang and Marraffini, 2015).  
After site recognition through sgRNA, 
the Cas9 cleaves the target generating blunt-
ended double-strand breaks (DSB) (Markos-
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sian et al., 2018; Billon et al., 2017; Jinek et 
al., 2012; La Russa and Qi, 2015; Komor et 
al., 2017; Jubair and McMillan, 2017; 
Pelletier et al., 2015). The DSB can be re-
paired by error-prone NHEJ or by the high-
fidelity homology-directed repair (HDR) 
(Hsu et al., 2014; Pelletier et al., 2015; 
Kocher et al., 2017). The first pathway may 
generate gene knockout and may be expand-
ed to multiple target sites mediating larger 
editing in the genomes. HDR, through re-
combination, may create allelic substitution, 
with a promised perspective in disease thera-
py (Jubair and McMillan, 2017; Kocher et 
al., 2017; Rivera-Torres et al., 2017). 
Variants of wild Cas9 have been devel-
oped. Inactivation of one of the catalytic 
domain leads to Cas9 nickase (Cas9n) strate-
gy which cleaves one of the two strands of 
target DNA (Gasiunas et al., 2012; Nakajima 
et al., 2018; Zhao et al., 2017; Kurihara et 
al., 2017; Sakuma et al., 2016). The catalyti-
cally dead version of Cas9 (dCas9) has both 
nuclease domains mutated and has been em-
ployed for transcription and epigenetic regu-
lation (Gilbert et al., 2013; Pulecio et al., 
2017; Chen et al., 2017; Hao et al., 2017; 
Adamson et al., 2016; Klann et al., 2017). 
dCas9 may bind to promoter sequences or 
open reading frames modulating gene ex-
pression in DNA level (Lundh et al., 2017; 
Gilbert et al., 2014; Cheng et al., 2013; 
Maeder et al., 2013; Mandegar et al., 2016; 
Duellman et al., 2017). This variation of 
CRISPR-Cas technique can act in ncRNAs 
as microRNAs (miRNAs) and any other ge-
nomic region and enables fusing of fluores-
cent proteins for DNA visualization (Jiang 
and Marraffini, 2015; Liu et al., 2017; Ye et 
al., 2017; Knight et al., 2018; Dominguez et 
al., 2016). The understanding of conforma-
tional R-loop dynamics and RNA: DNA in-
teractions are necessary for a better design of 
specific sgRNAs and their variants 
Cas9/dCas9-based (Josephs et al., 2015). 
The molecular genomic strategy 
CRISPR-Cas9-based has been exploited for 
biological and medical applications (Komor 
et al., 2017; Kwarteng et al., 2017; Kurihara 
et al., 2017; Sakuma et al., 2016; Zhao et al., 
2017; Josephs et al., 2015). Optimization of 
5’ sequence of the sgRNA and chemical 
modifications of Cas9 have been achieved to 
control off-targets and unspecific cleavages, 
maximizing the on-target activity (Chira et 
al., 2017; Cao et al., 2016; Josephs et al., 
2015). Moreover, Cas9 coding sequence has 
been introduced in different viral vector in-
cluding retroviral, lentiviral, and adeno-
associated (Senís et al., 2014; Sürün et al., 
2018), as well as in high-capacity adenoviral 
vectors in order to improve editing machine 
(Ehrke-Schulz et al., 2017; Hsu et al., 2014).  
In fact, CRISPR-Cas9 has overcoming 
other nuclease-based systems, such as Zinc 
Finger Nucleases (ZFNs) and Transcription 
Activator-Like Effector Nucleases 
(TALENs) (Kwarteng et al., 2017; Chira et 
al., 2017; Hsu et al., 2014; La Russa and Qi, 
2015; Larson et al., 2013; Pelletier et al., 
2015). It has been explored as a molecular 
tool for basic and applied research with ther-
apy purposes in human diseases and life sci-
ences (La Russa and Qi, 2015; Larson et al., 
2013; Pelletier et al., 2015; Aquino-Jarquin, 
2017). Nanotechnology has been reached in 
CRISPR-Cas9 to increase edited cells 
(Carlson-Stevermer et al., 2017). This tech-
nique represents an expanding area for inter-
rogating genetic elements and functions, 
controlling site-directed mutation and modu-
lating gene expression (Jubair and McMillan, 
2017). 
 
Applications of gene surgery 
Genome editing 
The DNA recombinant technology de-
veloped in the 1970s remarkable the new bi-
ology, enabling to engineer DNA molecules. 
This modern biotechnology established link-
ages between genetic variations and biologi-
cal phenotypes (Ishino et al., 1987; Mojica et 
al., 2000; Hsu et al., 2014). The traditional 
gene therapy based on vector-mediated over-
expression methods was developed to supply 
the cells with the functional gene copies for 
monogenic recessive diseases (Hsu et al., 
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2014). Currently, the gene therapy using the 
CRISPR-Cas9 system is suited for recessive 
and dominant inherited monogenic disorders 
(Jiang and Marraffini, 2015; Kocher et al., 
2017; Sürün et al., 2018).  
Virtually, CRISPR-Cas9 can repair en-
dogenous mutations and insert specific or 
random mutations (Pelletier et al., 2015). In 
this sense, Cas9 may be used to correct sin-
gle nucleotide polymorphism (SNP) where at 
least one copy of the functional gene can be 
expressed in its natural environment (Hsu et 
al., 2014). If the monogenic disease is due to 
the duplication of genomic sequences, Cas9 
may be exploited to delete the duplicated se-
quences. For the expansion of trinucleotide 
repeats two simultaneous DSBs may excise 
the repeat region (Hsu et al., 2014). For 
monogenic dominant disorders, the NHEJ 
may inactivate the mutant allele, and the 
sgRNA will be designed targeting to the spe-
cific allele with the SNP (Hsu et al., 2014). 
Rare diseases can also benefit from Cas9 
technology (Pelletier et al., 2015; Kocher et 
al., 2017). Using this system is possible to 
prevent non-genomic elements as virus 
(Kwarteng et al., 2017; Sakuma et al., 2016; 
Pelletier et al., 2015), by the promotion of 
mutation and repair NHEJ-mediated, cir-
cumventing infection without the need for 
continuing treatment (Kwarteng et al., 2017; 
Pelletier et al., 2015). The CRISPR-Cas9 
multiplexed with the Cas9n vector can re-
duce viral replication (Sakuma et al., 2016).  
The perturbation of multiple genes simul-
taneously can also allow the discovery of 
new generation drugs and therapeutics, test-
ed in the cell or transgenic animal created 
through CRISPR-Cas pathway (Jiang and 
Marraffini, 2015, Hsu et al., 2014, Pelletier 
et al., 2015, Kocher et al., 2017). The animal 
models CRISPR-Cas9-based have been pro-
duced to overcome the delivery challenges 
and to provide tools for in vivo or ex vivo 
study of mutations associated with human 
diseases (Dai et al., 2018; Erard et al., 2017; 
Jiang and Marraffini, 2015; Long et al., 
2014; Wangensteen et al., 2018; Wu et al., 
2013; Markossian et al., 2018; Hsu et al., 
2014; Platt et al., 2014; Kocher et al., 2017; 
Shi et al., 2017). The most well-known ob-
jective considering CRISPR-Cas9 involves 
the generation of frameshift indels (insertion 
or deletion) of random mutations in single or 
multiple genes at once to better understand 
cellular physiology (Komor et al., 2017; 
Markossian et al., 2018; Billon et al., 2017; 
Pelletier et al., 2015; Jiang and Marraffini, 
2015). The development of a multi-color and 
multi-locus Cas9 proteins or sgRNAs by la-
beling with fluorescent molecules can be an 
alternative method to the traditional probe 
DNA labeling, providing living cell imaging 
about complex chromosomal architecture 
and nuclear organization (Jiang and 
Marraffini, 2015; Liu et al., 2017; Ye et al., 
2017; Dominguez et al., 2016; Knight et al., 
2018; Hsu et al., 2014). 
Genome editing can promote either 
chromosomal biallelic or monoallelic frame-
shift mutations (Platt et al., 2014). Chromo-
somal alterations are efficiently generated by 
large insertions or deletions that disrupt intra 
or intergenic regions by DSBs (Zuo et al., 
2017; Pelletier et al., 2015). Moreover, 
chromosomal translocation can also be pro-
duced using an HDR oligonucleotide with 
sequence homology to both chromosomal 
locus and co-injected with CRISPR-Cas9 
(Pelletier et al., 2015). 
Genetic and epigenetic regulation of gene 
expression 
In the central dogma of molecular biolo-
gy is the combined control of gene expres-
sion coordinating the events of gene tran-
scription and translation, as the turnover of 
RNAs and proteins. The dysregulation of 
gene expression often results in cancer, met-
abolic disorders, cardiovascular and other 
human diseases (Komor et al., 2017; La 
Russa and Qi, 2015; Chen and Qi, 2017). 
Significant efforts have been devoted to en-
gineering transcriptional factors to control 
biological processes and, thereby, create new 
therapeutic strategies (Gilbert et al., 2013).  
The regulatory strategies using dCas9 
can produce levels of gene control without 
precedent (La Russa and Qi, 2015). The con-
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trol of the transcriptional regulation is crucial 
for understanding cellular behavior and 
dCas9 targeting regions upstream or down-
stream of the transcription start site modu-
lates cellular response (Braun et al., 2016). 
Regulation of gene expression by CRISPR-
dCas9 system is termed as CRISPRa for 
gene activation or CRISPRi for gene repres-
sion (Komor et al., 2017; Gilbert et al., 2013; 
La Russa and Qi, 2015; Perez-Pinera et al., 
2013; Chen and Qi, 2017), becoming versa-
tile when multiple sgRNAs/dCas9 fusions 
are multiplexed to regulate multiple targets 
within the same pathway (La Russa and Qi, 
2015). For example, dCas9 may be em-
ployed as a transporter protein directed to 
specific or multiple loci guided by sgRNA, 
activating or repressing gene expression 
(CRISPRa/i) (Komor et al., 2017; Chen and 
Qi, 2017; La Russa and Qi, 2015; Perez-
Pinera et al., 2013). 
However, it is noteworthy that genome 
organization in eukaryotes is complex and 
DNA regulatory elements can be far from 
the transcriptional start point. Epigenome al-
so coordinates gene expression, and chroma-
tin remodeling and chemical modifications 
of histones must be taken into account for 
expression regulation (Gilbert et al., 2013). 
Three-dimensional organization of chroma-
tins exerts a putative role in gene expression, 
and how chromatin loops are involved in this 
process needs to be clarified. In this field, 
CRISPR/dCas9 may interfere in nuclear ar-
chitecture demonstrating the power of this 
system to reorganize chromatin loops 
(Morgan et al., 2017).  
The gene expression by epigenome edit-
ing can be regulated by dCas9:sgRNA com-
plex using combinations of synthetic tran-
scription factors to bind near the transcrip-
tional endogenous human gene promoters 
with a relevant role in medicine (Komor et 
al., 2017; Cheng et al., 2013; Perez-Pinera et 
al., 2013; Polstein and Gersbach, 2015). The 
co-recruitment of multiple activators may be 
the strategies to produce the second genera-
tion of CRISPRa (La Russa and Qi, 2015). 
The transcriptional activation domain VP64 
from Herpes Simplex Viral Protein 16, fused 
with dCas9 (dCas9-VP64) was used to mod-
ulate the expression of a wide gene (Komor 
et al., 2017; Guo et al., 2017; Balboa et al., 
2015; Perez-Pinera et al., 2013). The dCas9 
fused to a histone acetyltransferase stabilized 
the expression of a transcription factor regu-
lated by epigenetic modification in inflam-
matory conditions modulating cellular re-
sponse (Okada et al., 2017). 
Alternatively, CRISPRi is an approach 
for perturbing gene expression with selec-
tivity to RNA polymerase, transcription 
elongation and/or with the sgRNA binding to 
specific DNA targeting the protein-coding 
region on a genome-wide scale (Jiang and 
Marraffini, 2015; Chen and Qi, 2017). The 
use of CRISPRi represents an exciting field 
to the counterpart RNA interference (RNAi) 
(Jiang and Marraffini, 2015; La Russa and 
Qi, 2015; Larson et al., 2013). The use of 
quantitative fluorescence assays and native 
elongating transcript sequencing was de-
scribed to produce a protocol for gene silenc-
ing at the transcriptional level through sgR-
NA providing the repression activity of 
CRISPRi as a complementary approach to 
RNAi (Larson et al., 2013). 
The advantage and disadvantages of the 
use of RNAi and CRISPRi need to be sys-
tematically evaluated about the effectivity in 
each different type of cell. In the CRISPRi 
system, the bioinformatics modeling identi-
fying high-confidence hits to generate sgR-
NAs directed to the target and testing large 
pools is important to find the ideal sgRNAs 
reducing off-targets (Erard et al., 2017; La 
Russa and Qi, 2015). The success of the 
CRISPR-Cas/dCas system has empowering 
researchers to better understand prokaryotic 
and eukaryotic genome functions and biolo-
gy system (Jiang and Marraffini, 2015; Hsu 
et al., 2014).  
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Molecular mechanism-mediated gene  
surgery 
Obesity 
Obesity affects nearly 500 million people 
worldwide and is at risk of developing cardi-
ovascular disorders, cancer, and type 2 dia-
betes (Garcίa-Jiménez et al., 2016). Obesity 
is primarily due to a positive energy balance, 
whereby the energy consumption exceeds 
expenditure, leading to energy storage, pre-
dominantly as lipids in white adipocytes 
(Claussnitzer et al., 2015). Notably, severely 
obese patients had medical costs that were 
$1980 higher annually per capita, compared 
to that of individuals within a normal body 
mass index (BMI) (Julie and Jacob, 2015). 
BMI comprised of strong genetic compo-
nents (40 to 80 % heritability) with several 
genes expressed in the hypothalamus and 
plays a crucial role in appetite regulation 
(Locke et al., 2015). 
Investigators at MIT, Havard University, 
and the Broad Institute of Cambridge had 
identified a variant of the fat mass and obesi-
ty-associated (FTO) gene that is responsible 
for the development of fat cells in the body 
and thus it is considered as one of the prima-
ry factors for weight gain (Claussnitzer et al., 
2015). However, what is worth to mention 
here was not the isolation of the FTO gene 
variant, the researchers were able to modify 
the living cells in mice that carrying variant 
using CRISPR-Cas9 (Maclean, 2016).  
Using DNA editing tools, they have iden-
tified a genetic switch that facilitates the 
regulation of body metabolism. The switch 
governs whether common fat cells burn en-
ergy or store it as fat (Vogel, 2015). 
CRISPR/Cas9 also can be used to convert 
the obesity-promoting FTO gene in adipo-
cyte precursor cells. The treated cells had 
lowered IRX3 and IRX5 expression, and ul-
timately spun up the energy-burning ma-
chinery (Claussnitzer et al., 2015). 
In another study, Yue et al. (2017) re-
ported that CRISPR-mediated genome edit-
ing controlled the release of glucagon-like 
peptide 1 (GLP1), a crucial incretin that reg-
ulates blood glucose homeostasis. In this 
study, GLP-1 induction from engineered 
mouse cells grafted onto immunocompetent 
hosts would be triggered by the administra-
tion of the antibiotic doxycycline, which 
subsequently reduces the appetite and de-
creases the high fat diet-induced obesity. 
Importantly, GLP-1 induction can reverse 
the high-fat diet-induced weight gain. There-
fore, the ability in the manipulation of the 
uncovered pathway, such as overexpression 
or knockdown of the upstream regulator AR-
ID5B, a genome editing of the predicted 
causal variant rs1421085, and overexpres-
sion or knockdown of target genes IRX5 and 
IRX3, had a prominent effect on obesity phe-
notypes. 
Cancer 
As a consequence of the global rise of 
obesity, the current and future burden of 
cancers associated with obesity tends to in-
crease. This is not only affecting the occur-
rence of cancer, a high prevalence of obesity 
also affects prognosis among cancer survi-
vors (Arnold et al., 2016). Cancer is a dis-
ease featured by multiple epigenetic and ge-
netic alterations in tumor suppressor genes 
and oncogenes (Deben et al., 2016). All can-
cers exert stepwise mutations that allow the 
cells to multiply and exhibit their malignan-
cy features (Economides et al., 2017; Xu et 
al., 2017). Cancer is genetically complex 
with hundreds of translocations, mutations, 
and chromosome losses and gains per tumor 
(Greer et al., 2017). Inappropriate activation 
of Wnt pathway has linked with different 
types of cancers. Loss of the adenomatous 
polyposis coli (APC) gene function induces a 
premalignant precursor lesion, which is a 
hallmark of human colorectal cancers (CRC) 
(Novellasdemunt et al., 2015). Given the ad-
vance in comprehensive structural character-
ization in cancer genomes and sequencing 
technology (Vogelstein et al., 2013), the mu-
tations in the Wnt pathway frequently impli-
cated in human cancers (Duchartre et al., 
2016). Although the fact that most of the 
pathway components have been character-
ized, the function of Wnt pathway within the 
context of cancer biology is intriguingly 
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complex and yet fully understood (Zhan et 
al., 2017).  
Over the past decades, research and de-
velopment on genome engineering technolo-
gies have made it possible to modify or pre-
cisely delete specific DNA sequences in the 
genome of the cells or animal models 
(Sánchez-Rivera and Jacks, 2015). The abil-
ity to correct such mutations is a primary 
goal in cancer treatment. There is substantive 
evidence based on the role of genome editing 
with CRISPR/Cas9 as a rapid genetic ma-
nipulation approach in any genomic locus 
(Dow et al., 2015). 
It is also demonstrated that CRISPR/ 
Cas9 system has been used to generate can-
cer cells from mouse primary cells or in vivo 
tissue (Heckl et al., 2014; Xue et al., 2014). 
Even though the requirement of Wnt-β-
catenin signaling axis in RNF43-mutated 
pancreatic ductal adenocarcinoma (PDAC) 
(Jiang et al., 2013b), the genetic complexity 
in this pathway for example co-receptors and 
intracellular signaling components, frizzled 
(FZD) receptors and Wnt ligands made the 
prediction of this therapeutic targets become 
difficult. Therefore, identification of this 
specific genetic vulnerability using genome-
wide CRISPR-based genetic screens may 
provide an unbiased and powerful means to 
identify context-specific fitness genes that 
can be harnessed in the treatment of cancer. 
Genome screening using CRISPR/Cas9 ena-
bles the detection of the Wnt-FZD5 signaling 
circuit in an RNF43-mutant pancreatic tumor 
(Steinhart et al., 2017). 
Treating de novo Kaposi's sarcoma-
associated herpesvirus (KSHV)-infected en-
dothelial cells with epilipoxinand lipoxinex-
hibits an anti-inflammatory effect by reduc-
ing the nuclear factor kappa B(NF-κB), ex-
tracellular signal–regulated kinase ½ 
(ERK1/2), cyclooxygenase-2(COX-2), 5-
lipoxygenase, and Akt expression. Further-
more, treatment with lipoxinusing CRISPR/ 
Cas9 technology-mediated lipoxin A4 recep-
tor/formylpeptidyl receptor (ALX/FPR) gene 
deletion implied the efficiency of lipoxin re-
ceptor ALX in lipoxin signaling (Chandra-
sekharan et al., 2016). In this study, a viral 
miRNA cluster has been identified as an im-
portant factor in the downregulation of lipox-
in A4 secretion in the host cells (Chandra-
sekharan et al., 2016). Additionally, De Rav-
in et al. (2017) also demonstrated that 
CRISPR/Cas9 could repair a mutation in the 
CYBB gene of CD34+ hematopoietic stem 
and progenitor cells (HSPCs) for those of the 
patients with immunodeficiency disorder X-
linked chronic granulomatous disease (X-
CGD). The beta-hemoglobinopathies, such 
as beta-thalassemia and sickle cell disease 
are caused by beta-globin (HBB) gene muta-
tions which had affected millions of people 
worldwide. Surprisingly, using CRISPR-
based methodology the ex vivo gene can be 
corrected in patient-originated hematopoietic 
stem cells after autologous transplantation.  
The miRNAs play a crucial role in the 
development of breast cancer. An earlier 
study has reported that miRNAs expression 
was changed significantly in cancer cell lines 
and tumor tissues (Ji et al., 2017). miRNA 
dysfunction is a biomarker in various patho-
logical diseases such as cancer (Ji et al., 
2017). Therefore, miRNA has been recog-
nized as a robust biomarker in ovarian, pros-
tate, and ovarian cancers for therapeutic tar-
geting (Smith et al., 2017). This potential 
therapeutic effect has been demonstrated by 
Abdollah et al. (2017), who found that the 
expression of miR-130a-5p was downregu-
lated in breast cancer (MCF7) cell line using 
CRISPR silencing system. It was also re-
vealed from several in vitro and in vivo stud-
ies that this editing tool has potential in inhi-
bition of cancer cell growth and increases 
cell apoptosis (Liu et al., 2014; Zhen et al., 
2017). Importantly, CRISPR systems are be-
ing applied to ameliorate genetic disorders in 
animals and seem to be employed in human 
diseases (Barrangou and Doudna, 2016). The 
prospects of this gene-editing technology 
trigger a biomedical duel in China when the 
CRISPR-Cas9 technique was first introduced 
to a patient with aggressive lung cancer at 
West China Hospital, Chengdu (Cyranoski, 
2016). 
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In addition to the significant therapeutic 
approach of in vivo somatic genome editing 
to alter genetic defects (Long et al., 2014; 
Yin et al., 2014), its applications in cancer 
modeling have been convincingly reported 
(Table 1). For instance, several groups have 
demonstrated that direct in vivo delivery of 
the relevant gRNA and Cas9 to the specific 
tissue using viral vectors or naked DNA can 
be used to initiate tumorigenesis and sup-
press somatically tumor-suppressor genes 
(Platt et al., 2014; Xue et al., 2014; Chiou et 
al., 2015; Zuckermann et al., 2015). This ap-
proach has been successfully utilized to inac-
tivate the tumor suppressor genes such as 
liver kinase B1 (Lkb1), transformation-
related protein 53 (Tp53), phosphatase and 
tensin homolog (Pten), and adenomatous 
polyposis coli (APC) in the lungs of adult 
mice (Platt et al., 2014). Preclinical findings 
from in vitro and in vivo studies on mecha-
nisms involved in cancer suggest that the 
CRISPR-Cas9 technique could modulate 
pathway involving in cancers. Targeting the 
cancer cells nucleotide sequences with the 
cellular genome is an attractive approach. 
Collectively, the ability to correct the cancer-
associated mutations has been identified as a 
powerful treatment option. These techniques 
facilitate in the correction of mutations in the 
cancer cells. 
Diabetes 
Diabetes is a chronic and metabolic dis-
ease featured by elevation of blood glucose 
levels, which cause serious damage to the 
blood vessels, eyes, heart, nerves, and kid-
neys (World Health Organization, 2017). 
According to the World Health Organization 
(2017), there are 422 million adults having 
diabetes with 1.6 million deaths annually 
(World Health Organization, 2017). 
CRISPR/Cas9 could alter the gene that is re-
sponsible for encoding a hormone known as 
glucagon-like peptide-1 (GLP-1). GLP-1 
promotes the release of insulin and facilitates 
in the reduction of glucose from the blood 
(Yue et al., 2017). This therapeutic potential 
was not only exhibited in in vivo genome ed-
iting, its applications in Type 1 diabetes in a 
mouse modeling have also been demonstrat-
ed. For example, Ptpn22R619W mice showed 
an increase in insulin autoantibodies and 
high susceptibility of Type 1 diabetes (Lin et 
al., 2016). Notably, inhibition of FOS/JUN 
pathway either through CRISPR-mediated 
suppression of FOS rescued the inability of 
CDKAL1 null cells to alter glycemia in strep-
tozotocin-diabetic mice (Rutter, 2016). Tak-
en together, these editing techniques hold 
great promise in future use in the treatment 
of diabetes.  
 
Table 1: Examples of cancer mouse models developed by CRISPR/Cas9 genome editing  
Authors Year Types of cancer Mutations Mouse strain 
Blasco et al.  2014 Lung  
adenocarcinoma 
Eml4‐Alk trans-
location in lung 
p53+/- or p53‐/‐ 
Xue et al. 2014 Liver cancer p53, Pten, 
Ctnb1 
FVB/NJ mice 
Aubrey et al. 2015 Burkitt lymphoma p53 HSPC from Eμ-Myc 
mice 
Chiou et al. 2015 Pancreatic ductal 
adenocarcinoma 
Lkb1 KrasLSL-G12D/+; 
R26LSL-Tom; 
H11LSL-Cas9/+ 
Dow et al. 2015 Intestinal hyperplastic 
polyps 
APC, Trp53 Doxycycline-
inducible Cas9 
Zuckermann et al. 2015 Medulloblastoma Ptch1 C57BL/6N mice 
Alk: Anaplastic lymphoma kinase; APC: Adenomatous polyposis coli; Ctnb1: Beta-catenin; Eml4: 
Echinoderm microtubule-associated protein-like 4; Lkb1: Liver kinase B1; Pten: Phosphatase and 
tensin homolog; Trp53: Transformation related protein 53; Ptch1: Protein patched homolog 1 
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Cardiovascular diseases 
Cardiovascular diseases (CVDs) are a 
major health problem and the leading cause 
of death globally (Go et al., 2013). Several 
polymorphisms have already been identified 
and implicated in the pathogenesis of CVDs 
and more continue to be located by scientists 
every day (Fiatal and Ádány, 2018). The 
emergence of gene-surgery technologies has 
given researchers new approaches to study 
and treat the common complex CVDs such 
as inherited cardiomyopathies, valvular dis-
eases, primary arrhythmogenic conditions, 
congenital heart syndromes, hypercholester-
olemia and atherosclerotic heart disease, hy-
pertensive syndromes, and heart failure with 
preserved/reduced ejection fraction (Pasi-
poularides, 2018). 
The three universally used tools are Zinc 
Finger Nucleases (ZFNs), Transcription Ac-
tivator-Like Effector Nucleases (TALENs), 
and the Clustered Regularly Interspaced 
Short Palindromic Repeats (CRISPR)-
associated Cas9 (CRISPR/Cas9) system 
(Termglinchan et al., 2016). Each system has 
its own advantages and limitations and has 
been applied in various scientific fields to 
increase the understanding of normal gene 
regulation and the pathophysiology of the 
disease, as well as to facilitate the develop-
ment of novel therapies (Seeger et al., 2017). 
One of the major goals of gene surgery is 
replacing defective, down-regulated, or miss-
ing genes with normal, enabling the normal 
function or, alternatively, adds a new gene to 
restore or improve well-being. In fact, there 
are different approaches for using gene edit-
ing according to two categories of CVDs: 
diseases caused by primary cardiomyopathy 
that could be corrected by genome editing 
within the cardiac muscle, and diseases sec-
ondarily caused by extracardiac influences 
(Strong and Musunuru, 2017). In the first 
category, the most likely example are the in-
herited cardiomyopathies, such as familial 
hypertrophic cardiomyopathy and dilated 
cardiomyopathy. In a large proportion of pa-
tients, these cardiomyopathies are caused by 
single dominant mutations within sarcomere 
genes (Musunuru, 2017). In principle, these 
diseases could be prevented or arrested by 
two different strategies: correction of the 
mutant allele by homology-directed repair 
(HDR), or allele-specific gene disruption via 
Non-Homologous End-Joining (NHEJ) strat-
egy, removing the dominant influence of the 
mutant allele (Jiang et al., 2013a, b).  
The first strategy might be extremely 
challenging to achieve owing to limited 
HDR in adult cardiomyocytes. An approach 
similar to the second strategy has been 
achieved in a mouse model through the use 
of RNA interference, suggesting the viability 
of the NHEJ genome-editing approach (Coe-
lho et al., 2013). The success of the NHEJ 
approach would depend on being able to 
achieve stringent specificity for the mutant 
allele, which usually differs from the wild-
type allele by only a single base pair. For 
CRISPR/Cas9, this specificity would be 
most feasible if the causal mutation created a 
point accepted mutation (PAM) site that was 
not present in the wild-type allele (Chong et 
al., 2014).  
The second category of diseases includes 
the treatment of hypercholesterolemia to re-
duce the risk of myocardial infarction, via 
the disruption of proprotein convertase sub-
tilisin/kexin type 9 (PCSK9) or other lipo-
protein regulators in the liver (Cai et al., 
2016). When PCSK9 is dysregulated, such as 
through gain-of-function mutations in the 
PCSK9 gene, the protein impairs low-density 
lipoprotein (LDL)-cholesterol clearance by 
acting as an antagonist to the LDL receptor, 
thereby promoting hypercholesterolemia. 
Conversely, naturally occurring loss-of-
function mutations reduce the risk of myo-
cardial infarction by markedly reducing 
blood cholesterol levels (Chadwick and 
Musunuru, 2017). Due to this observation, 
two antibody-based therapies targeting 
PCSK9 have been developed and recently 
approved; however, these therapies must be 
delivered by injection every few weeks (Ito 
and Santos, 2017). Another example is car-
diac amyloidosis, in which production and 
secretion of a mutant form of the transthyret-
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in (TTR) protein by the liver into the blood-
stream results in the accumulation of the mu-
tant protein within the cardiac muscle. Dis-
ruption of the TTR gene in the liver by ge-
nome editing might arrest or even reverse the 
cardiomyopathy, a goal currently being pur-
sued with RNA interference (Coelho et al., 
2013). 
A distinct approach to leveraging ge-
nome editing for the treatment of cardiovas-
cular disorders would be to perform the edit-
ing ex vivo. This might entail generating in-
duced pluripotent stem cells (iPSCs) from a 
patient, editing the iPSCs so as to correct a 
mutation or otherwise render the cells pro-
tective against disease, differentiating the ed-
ited iPSC into the desired cell type (such as 
cardiomyocytes), and transplanting the dif-
ferentiated cells back into the patient (Wu et 
al., 2018). Even though this approach re-
mains largely theoretical for CVDs. Current-
ly, efforts are directed toward complex, pol-
ygenic, chronic cardiac diseases, such as 
acute heart disease (AHD) and heart failure 
(HF) (Lim, 2017). 
The application of the gene surgery tools 
in CVDs presents a novel and rapidly ad-
vancing technology with promising results. 
However, significant challenges remain, in-
cluding enhancing specificity and minimiz-
ing off-target effects, increasing efficiency, 
and improving the selection of targeted sites 
and delivery methods, and especially for in 
vivo genome engineering. Further refine-
ments are needed to fully exploit the poten-
tial of genome editing to be a vital tool for 
future precision medicine treatment for 
CVDs. 
 
LIMITATIONS OF ZFNS, TALENS 
AND CRISPR/CAS 
Design difficulties and costs  
In spite of the multiple efforts carried out 
to simplify the gene-editing using ZFNs and 
TALENs, it still remains difficult, laborious 
and time-consuming. Scientists are facing 
more difficulties in building optimized ZFNs 
with high affinity. In fact, besides the lack of 
simple ZFN-generation technologies, the po-
sitional effects (position of the zing fingers 
on the protein and the nature of the neighbor-
ing fingers) make the ZFN-design more dif-
ficult and complex. In addition, the open-
source ZFNs have limited target site selec-
tion and present several practical limits (Lee 
et al., 2016; Gupta and Musunuru, 2014; Isa-
lan, 2012). Likewise, since the construction 
of new TALEN protein is based on the target 
sequence involving one-to-one recognition 
rules, it is considered difficult, expensive and 
time-consuming. On the other hand, the 
CRISPR/Cas9 system construction is simply 
based on the alteration of the crRNA se-
quence of the sgRNA (Chira et al., 2017).  
 
Off-target effects  
The ability of both homo or heterodimers 
of ZFNs and TALENs to recognize the site 
targets enhances the incidence of off-targets 
generation (Chandrasegaran and Carroll, 
2016; Carlson et al., 2012). It has been 
demonstrated that the binding affinity of 
ZFNs is context-dependent. Owing to the 
presence of resemblance between the target 
sequence sites and other sites resulting in a 
high number of targetable sites, ZFNs were 
shown to possess off-target recognition ac-
tivities and caused the generation of un-
known mutations and cytotoxicity (Li et al., 
2013; Pattanayak et al., 2014). Also, it has 
been found for ZFNs that a low homology of 
66 % to the target leads to an off-target 
cleaving. This resemblance level generating 
off-target activity was found to be 72 % for 
TALENs (Fine et al., 2014). A large number 
of off-target sites of ZFNs in human cells 
were identified using both in vitro and in sil-
ico approaches (Sander et al., 2013). To 
avoid cytotoxicity-induced by ZFNs off-
targets, commercial ZFNs (custom-made 
ZFNs) have been developed and were found 
to be more potent and specific. Unfortunate-
ly, the use of custom-made ZFNs in gene ed-
iting may be limited due to their high cost 
(Doudna and Sontheimer, 2014; Koo et al., 
2015). Likewise, TALENs have been shown 
to exhibit several off-targets. At least, three 
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COL7A1, two PPP1R12C, one CCR5 off-
targets in humans, and one IgM off-target in 
Rattus norvegicus were identified for 
TALENs (Grau et al., 2013). Mussolino et 
al. (2014) studied the off-target effects of 
TALENs and ZFNs on three human loci 
(CCR5, AAVS1, and IL2RG). The results of 
the bioinformatics-based analysis showed 11 
and 4 sites of ZFNs-, and TALENs-
associated off-target activity for CCR5 and 
AAVS1, respectively.  
In the same line, CRISPR-Cas nucleases 
were demonstrated to induce enhanced rates 
of off-target mutagenesis in human cells (Fu 
et al., 2013; Lin et al., 2014). Li et al. (2015) 
used the Bowtie program to search the off-
target-sequence-dependent mutations of both 
TALENs and CRISPR-Cas in the human ge-
nome. Thousands of off-targets sites were 
found for TALENs, whereas, five off-targets 
were identified for CRISPR-Cas. In another 
study using T cells, one off-target site was 
found for CRISPR/Cas9 in addition to six 
off-target sites for TALENs (Knipping et al., 
2017). Nonetheless, Veres et al. (2014) stud-
ied the off-target mutagenesis effects of 
TALENs and CRISPR-Cas9 in human plu-
ripotent stem cells through whole-genome 
sequencing. They reported a low incidence 
of off-target mutations related to TALENs 
and CRISPR-Cas9. Off-target activity asso-
ciated with ZFNs, TALENs and 
CRISPR/Cas may result in DNA damage 
leading to cytotoxicity, apoptosis and gross 
chromosomal rearrangements in the human 
cells (Hendel et al., 2015). Similarly, off-
targets mutations induced by CRISPR-Cas9 
caused cytotoxicity in other organisms such 
as Schizosaccharomyces pombe and Saccha-
romyces cerevisiae (Wang et al., 2016). It 
has been found that the off-target activity of 
CRISPR/Cas9 was due to the protospacer 
sequence in the g-RNA, which explains the 
fact that Cas9 is less precise in experimental 
studies when compared to the results ob-
tained via theoretical approaches (Crauciuc 
et al., 2017). Therefore, due to its important 
off-target activity, the use of the 
CRISPR/Cas9 in gene therapy could be con-
troversial (Kruminis-Kaszkiel et al., 2018) 
and several issues regarding its effectiveness 
and efficiency should be widely discussed.  
 
Efficiency and delivery 
To be used in the treatment of multigenic 
diseases such as cancer, CRISPR/Cas9 sys-
tem should target different sites on the ge-
nome. Constructing CRISPR/Cas9 targeting 
different loci means the use of multiple 
sgRNAs and co-transfection of vectors 
which results in more design complexity and 
less efficiency in vitro and in vivo (Chira et 
al., 2017). In spite of the recent advance-
ments in transfection technologies, it has 
been found that CRISPR/Cas9 delivery is 
limited due to the low transfection efficiency 
and the associated difficulties in transfecting 
the primary cells (Seki et al., 2018). 
One of the biggest challenges of gene 
therapy is the delivery of the genome editing 
molecules directly, efficiently and safely to 
the target cells within their tissues (Carroll, 
2016; Cox et al., 2015). The delivery of Cas9 
limits the efficiency of gene-editing and 
therapy (Liang et al., 2015). Actually, the 
CRISPR/Cas system faces important prob-
lems to be safely delivered in vivo. Indeed, 
the spCas9 are characterized by a large mo-
lecular size, similar or slightly smaller than 
that of their adeno-associated virus vectors. 
Furthermore, the negative charges of RNAs 
are considered an important obstacle to their 
diffusion across the cell membrane, besides 
their degradation induced by the endonucle-
ases (Bayat et al., 2018; Wang et al., 2016). 
 
Low incidence of homology-directed re-
combination (HDR) vs high level of NHEJ 
The use of CRISPR/Cas9 is characterized 
by an extremely low incidence of homology-
directed repair (HDR) found to be 0.5 – 
20 % and important non-homologous end-
joining (NHEJ) mechanism reaching 60-
100 % in mammalian cells (Lino et al., 2018, 
Li et al., 2017). It has been reported that low 
HDR hindered the efficiency of the CRISPR/ 
Cas9 system (Aird et al., 2018). Further-
more, the NHEJ leading to the generation of 
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Indels (insertions/deletions) at the DSBs, re-
sulted in several undesired chromosomal re-
arrangements and mutations of the target 
cells (Yanik et al., 2017). When compared to 
TALEN, Cas9 was shown to possess im-
portant NHEJ-inducing activity. Cas9 in-
duced NHEJ 10-fold more than HDR 
(Miyaoka et al., 2016). 
 
Ethical and regulatory problems of gene  
editing  
Recent advances in gene-editing technol-
ogies offer promising applications for treat-
ing and preventing human diseases, such as 
Parkinson’s, sickle cell anemia, cardiomyo-
pathy, infectious, and ischemic heart disease. 
However, many ethical issues have been 
raised by the use of these technologies in the 
edition of the human germline. This debate 
has attracted more attention after the devel-
opment of CRISPR/Cas9 and its variant 
methodologies that made genomic editing 
more accurate and even "easy" compared to 
older technologies.  
According to UNESCO's International 
Bioethics Committee (IBC), applications of 
CRISPR/Cas9 technology should be limited 
only to the preventative, diagnostic and ther-
apeutic procedures, without altering human 
embryos. In addition, scientists recognized 
that CRISPR/Cas9 application in human dis-
ease is not entirely safe and effective. An in-
ternational effort was also initiated to har-
monize regulation of the application of ge-
nome editing technologies. This effort offi-
cially launched in December 2015 with the 
International Summit on Human Gene Edit-
ing and focused on the clinical, ethical, legal 
and social issues of human gene editing.  
 
FUTURE PERSPECTIVE OF GENE 
SURGERY 
Despite different therapies and drugs that 
have been developed for disease treatment, 
the overall survival rates have not improved 
much over the last decades. The place of ap-
plication in CRISPR/Cas9 as a therapeutic 
approach is astounding. Research has shown 
that the potential of this gene surgery tech-
nology to permanently alter the genetic mu-
tations in vivo in the adult liver of mouse 
models of hereditary genetic disease via ho-
mology-directed repair (HDR) pathway, and 
successfully ameliorating the disorder (Yin 
et al., 2014). Not only that, the application of 
CRISPR-based somatic genome editing in 
mice models and other organisms has greatly 
accelerated the place of discovery. Perhaps 
the greatest challenge in the future is the ef-
ficiently delivery of CRISPR/Cas9 to the 
specific targeted cells and reduce the off-
target effects (White and Khalili, 2016). 
In addition, to enhance its specificity, 
other crucial limitations need to be overcome 
before the comprehensive of CRISPR-based 
genome editing has been realized. For in-
stance, despite available viral vectors have 
been employed, more effective techniques to 
deliver the gRNAs and the Cas enzyme to 
somatic cells of adult animals are needed. 
Furthermore, it is also important to enhance 
the efficiency of CRISPR-mediated gene ed-
iting for the induction of specific genetic 
changes such as gain-of-function mutations 
in oncogenes in vivo. This could be achieved 
by temporarily inhibiting NHEJ to improve 
HDR (Chu et al., 2015; Maruyama et al., 
2015). Although this gene-editing tool has 
some limitations, further advances of this 
gene therapy will undoubtedly come rapidly, 
given the intensity of research efforts in this 
area. 
 
CONCLUSIONS 
In the present review, we summarized the 
different applications of gene surgery for 
treating human diseases such as cancer, dia-
betes, nervous, and cardiovascular diseases, 
besides the molecular mechanisms involved 
in these important effects. Recent studies re-
veal that gene surgery continues to provide 
promising results regarding their therapeutic 
effects against retinal diseases, primary im-
munodeficiencies, neurological disorders, β-
thalassemia, hemophilia, diabetes, and can-
cers. Nonetheless, in spite of the important 
EXCLI Journal 2019;18:908-930 – ISSN 1611-2156 
Received: September 20, 2019, accepted: October 09, 2019, published: October 11, 2019 
 
 
922 
opportunities both in therapy and transla-
tional research and the recent technical ad-
vancements, gene surgery still presents some 
limitations such as the design difficulties and 
costs regarding ZFNs and TALENs use, off-
target effects, low transfection efficiency, in 
vivo delivery-safety and ethical issues.  
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